Skip to main content
SpringerLink
Log in

The cognition-enhancing drug tenilsetam is an inhibitor of protein crosslinking by advanced glycosylation

  • Full Papers
  • Published:
Journal of Neural Transmission - Parkinson's Disease and Dementia Section

Summary

Non-enzymatic glycosylation of proteins, also called Maillard reaction, which occurs at an accelerated rate in diabetes, can lead to the formation of advanced glycosylation endproducts (AGEs). Tenilsetam (®CAS 997: (±)-3-(2-thienyl)-2-piperazinone), a cognition-enhancing drug successfully used for treatment of patients suffering from Alzheimer's disease, when included in the Maillard reaction apparently inhibits protein crosslinking by AGEs in vitro. According to the mechanism proposed, Tenilsetam acts via covalent attachment to glycated proteins, thus blocking the reactive sites for further polymerisation reactions. A beneficial effect of Tenilsetam in Alzheimer's disease could come from the interference with AGE-derived crosslinking of amyloid plaques and a decreased inflammatory response by diminished activation of phagocytosing microglia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Ajiboye R, Harding JJ (1989) The non-enzymatic glycosylation of bovine lens proteins by glucosamine and its inhibition by®Aspirin, ibuprofen and glutathione. Exp Eye Res 49: 31–41

    Article  PubMed  Google Scholar 

  • Beyreuther K, Multhaupt G, Masters CL (1993) Disentanglement from Alzheimers disease. In: Maurer K (ed) Dementias: neurochemistry, neuropathology, neuroimaging, neuropsychology, genetics. Vieweg, Braunschweig, pp 103–118

    Google Scholar 

  • Blakytny R, Harding JJ (1992) Prevention of cataract in diabetic rats by®Aspirin, paracetamol (acetaminophen) and ibuprofen. Exp Eye Res 54: 509–518

    Article  PubMed  Google Scholar 

  • Brion JP, Cheetham ME, Coleman M, Dale G, Gallo JM, Hanger DP, Probst A, Smith DC, Anderton BH (1990) Molecular and cellular changes associated with neurofibrillary tangles and senile plaques. In: Maurer K, Riederer P, Beckmann H (eds) Alzheimer's disease. Epidemiology, neuropathology, neurochemistry and clinics. Springer, Wien New York, pp 131–139

    Google Scholar 

  • Brownlee M (1991) Glycosylation products as toxic mediators of diabetic complications. Annu Rev Med 42: 159–166

    Article  PubMed  Google Scholar 

  • Brownlee M, Vlassara H, Cerami A (1986) Trapped immunoglobulins on peripheral nerve myelin from patients with diabetes mellitus. Diabetes 35: 999–1003

    PubMed  Google Scholar 

  • Buccala R, Cerami A (1992) Advanced glycosylation: chemistry, biology, and implications for diabetes and aging. Adv Pharmacol 23: 1–34

    PubMed  Google Scholar 

  • Cerami A, Vlassara H, Brownlee M (1988) Role of advanced glycosylation products in complications of diabetes. Diabetes Care 11[Suppl 1]: 73–79

    PubMed  Google Scholar 

  • Cherian M, Abraham EC (1993) In vitro glycation and acetylation (by®Aspirin) of rat crystallins. Life Sci 52: 1699–1707

    Article  PubMed  Google Scholar 

  • Cullum NA, Mahon J, Stringer K, McLean WG (1991) Glycation of rat sciatic nerve tubulin in experimental diabetes mellitus. Diabetologia 34: 387–389

    Article  PubMed  Google Scholar 

  • Dierks T, Maurer K, Ihl R (1989) Influence of tenilsetam on AEP-300 in Alzheimer's disease. J Neural Transm [P-D-Sect] 1: 49

    Google Scholar 

  • Dominiczak MH (1991) The significance of the products of the Maillard (browning) reaction in diabetes. Diabet Med 8: 505–516

    PubMed  Google Scholar 

  • Domino EF, Wilson AE (1972) Psychotropic drug influence on brain acetylcholine utilisation. Psychopharmacologia 25: 291–298

    Article  PubMed  Google Scholar 

  • Dyer DG, Blackledge JA, Thorpe SR, Baynes JW (1991) Formation of pentosidine during nonenzymatic browning of proteins by glucose. Identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. J Biol Chem 266: 11654–11660

    PubMed  Google Scholar 

  • Finot PA, Furniss DE (1989) Metabolic transit and toxicity of Maillard reaction products. Prog Clin Biol Res 304: 343–358

    PubMed  Google Scholar 

  • Grandhee SK, Monnier VM (1991) Mechanism of formation of the Maillard protein cross-link pentosidine. Glucose, fructose and ascorbate as pentosidine precursors. J Biol Chem 266: 11649–11653

    PubMed  Google Scholar 

  • Guzdek A, Stalinska K (1992) Glycated proteins as inducers of acute phase cytokines. Fol Histochem Cytobiol 30: 167–169

    Google Scholar 

  • Harding JJ (1993) Alzheimer's disease (AD), modified proteins and®Aspirin (letter). Alzheimer Dis Assoc Disord 7: 55–58

    PubMed  Google Scholar 

  • Hoyer S (1988) Glucose and related brain metabolism in dementia of Alzheimer type and its morphological significance. Age 11: 158–166

    Google Scholar 

  • Hoyer S (1992) Oxidative energy metabolism in Alzheimer brain. Studies in early-onset and late-onset cases. Mol Chem Neuropathol 16: 207–224

    PubMed  Google Scholar 

  • Hoyer S (1993) Sporadic dementia of Alzheimer type: role of amyloid in etiology is challenged (Editor's note for debate). J Neural Transm [P-D Sect] 6: 159–165

    Google Scholar 

  • Hoyer S, Nitsch R, Oesterreich K (1991) Predominant abnormality in cerebral glucose utilization in late-onset dementia of the Alzheimer type: a cross-sectional comparison against advanced late-onset and incipient early-onset cases. J Neural Transm [P-D Sect] 3: 1–14

    Article  Google Scholar 

  • Ihl R, Perisic I, Maurer K, Dierks T (1989) Effect of 3 months treatment with tenilsetam in patients suffering from dementia of Alzheimer type (DAT). J Neural Transm [P-D Sect] 1: 84–85

    Google Scholar 

  • Kato M (1990) The development of radioimmunoassay and studies of removal system for advanced glycosylation endproduct. Hokkaido Igaku Zasshi 65: 152–160

    PubMed  Google Scholar 

  • Lewis BS, Harding JJ (1990) The effect of aminoguanidine on the glycation (non-enzymatic glycosylation) of lens proteins. Exp Eye Res 50: 463–467

    Article  PubMed  Google Scholar 

  • Maillard LC (1912) Action des acides amines sur les sucres; formation des melanoidines par voie methodique. CR Hebd Seances Acad Sci 154: 66–68

    Google Scholar 

  • Miyata S, Monnier V (1992) Immunohistochemical detection of advanced glycosylation end products in diabetic tissue using monoclonal antibody to pyrraline. J Clin Invest 89: 1102–1112

    PubMed  Google Scholar 

  • Miyata T, Oda O, Inagi R, Iida Y, Araki N, Yamada N, Horiuchi S, Taniguchi N, Maeda K, Kinoshita T (1993) Beta 2-Microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis. J Clin Invest 92: 1243–1252

    PubMed  Google Scholar 

  • Monnier VM (1989) Towards a Maillard reaction theory of aging. Prog Clin Biol Res 304: 1–22

    Google Scholar 

  • Monnier VM, Cerami A (1981) Nonenzymatic browning in vivo: possible process for aging of long-lived proteins. Science 211: 491–493

    Google Scholar 

  • Monnier VM, Sell DR, Miyata S, Nagaraj RH (1900) The Maillard reaction as a basis for a theory of aging. In: Finot PA, Aeschbacher HU, Hurell RF, Liardon R (eds) The Maillard reaction in food processing, human nutrition and physiology. Birkhäuser, Basel Boston Berlin, pp 393–414 (Advances in life sciences)

    Google Scholar 

  • Nagaraj RH, Monnier VM (1992) Isolation and characterisation of a blue fluorophore from human eye lens crystallins: in vitro formation from Maillard reaction with ascorbate and ribose. Biochim Biophys Acta 1116: 34–42

    PubMed  Google Scholar 

  • Odetti PR, Borgoglio A, De Pascale A, Rolandi R, Adezati L (1990) Prevention of diabetes increased aging effect on rat collagen linked fluorescence by aminoguanidine and rutin. Diabetes 39: 796–801

    PubMed  Google Scholar 

  • Pepeu G, Spignoli G (1989) Nootropic drugs and brain cholinergic mechanisms. Prog Neuropsychopharmacol Biol Psychiatry 13: S77-S88

    Article  PubMed  Google Scholar 

  • Pugsley TA, Shih YH, Coughenor L, Stewart SF (1983) Some neurochemical properties of pramiacetam (CI-879), a new cognition enhancing agent. Drug Dev Res 3: 407–420

    Article  Google Scholar 

  • Rogers J, Cooper NR, Webster S, Schultz J, McGeer PL, Styren SD, Civin WH, Brachowa L, Bradt B, Ward P (1992) Complement activation by beta-amyloid in Alzheimer's disease. Proc Natl Acad Sci USA 89: 100016–100020

    Google Scholar 

  • Saletu B, Grünberger J, Cepko H (1986) Pharmacokinetic and-dynamic studies in elderelies with a potential antihypoxidotic/nootropic drug utilising pharmaco-EEG and psychometry. Drug Dev Res 9: 95–113

    Article  Google Scholar 

  • Saletu B, Semlitsch H, Anderer P, Resch F, Presslich O, Schuster P (1989) Psychiophysiological research in psychiatry and neuropsychopharmacology II. The investigation of antihypoxidotic/nootropic drugs (tenilsetam and co-dergocrine-mesylate) in elderlies with the Viennese psychophysiological test-system (VPTS). Meth Find Exp Clin Pharmacol 11: 43–55

    Google Scholar 

  • Schindler U (1989) Pre-clinical evaluation of cognition enhancing drugs. Prog Neuropsychopharmacol Biol Psychiatry 13: S99-S115

    Article  PubMed  Google Scholar 

  • Schindler U, Beyerle R, Nitz RE (1985) Pharmacological effects on the novel compound tenilsetam (®CAS 997) on learning and memory impairment. Naunyn Schmiedebergs Arch Pharmacol 330[Suppl]: R75

    Google Scholar 

  • Schlondorff D (1993) Cellular mechanisms of lipid injury in the glomerulus. Am J Kidney Dis 22: 72–82

    PubMed  Google Scholar 

  • Schmidt AM, Yan SD, Brett J, Mora R, Nowygrod R, Stern D (1993) Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products. J Clin Invest 91: 2155–2168

    PubMed  Google Scholar 

  • Schnabel J (1993) New Alzheimer's theraphy suggested [news]. Science 260: 1719–1720

    PubMed  Google Scholar 

  • Shapira R, Austin GE, Mirra SS (1988) Neuritic plaque amyloid in Alzheimer's disease is highly racemized. J Neurochem 50: 69–74

    PubMed  Google Scholar 

  • Spignoli G, Pepeu G (1986) Oxiracetam prevents electroshock-induced decrease in brain acetylcholine and amnesia. Eur J Pharmacol 126: 252–257

    Article  Google Scholar 

  • Spignoli G, Pepeu G (1987) Interaction between oxiracetam, aniracetam and scopolamine on behaviour and brain acetylcholine. Pharmacol Biochem Behav 27: 491–495

    Google Scholar 

  • Stevens VJ, Rouzer CA, Monnier VM (1978) Diabetic cataract formation: potential role of glycosylation of lens proteins. Proc Natl Acad Sci USA 75: 2918–2922

    PubMed  Google Scholar 

  • Van Boekel MA (1991) The role of glycation in aging and diabetes mellitus-minireview. Mol Biol Reports 15: 57–64

    Article  Google Scholar 

  • Van Boekel MA, van den Bergh PJPC, Hoenders HJ (1991) Glycation of human serum albumin: inhibition by®Diclophenac. Biochem Biophys Acta 1120: 201–204

    Google Scholar 

  • Vernon MW, Sorkin EM (1991) Piracetam. An overview of its pharmacological properties and a review of its therapeutic use in senile cognitive disorders. Drugs Aging 1: 17–35

    PubMed  Google Scholar 

  • Vlassara H, Brownlee M, Manogue K, Dinarello C, Pasagian A (1988) Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. Science 240: 1546

    PubMed  Google Scholar 

  • Walker DG, McGeer PL (1992) Complement gene expression in human brain: comparison between normal and Alzheimer's disease cases. Brain Res Mol Brain Res 14: 109–116

    Article  PubMed  Google Scholar 

  • Wesnes K, Simpson PM, Kidd A (1987) The use of a scopolamine model to study the nootropic effects of tenilsetam (®CAS 997) in man. Med Sci Res 15: 1063–1064

    Google Scholar 

  • Wu H, Hartman TG, Govindaraj S, Kahn PC, Ho CT, Rosen JD (1991) Glycation of lysozyme in a restricted water environment. Proc Natl Sci Counc Repub China B (1991) 15: 140–146

    Google Scholar 

Download references

Author information

Author notes

  1. P. Riederer

    Present address: Klinische Neurochemie, Universitäts-Nervenklinik, Füchsleinstrasse 15, D-97080, Würzburg, Federal Republic of Germany

Authors and Affiliations

  1. Klinische Neurochemie, Universitäts-Nervenklinik, Füchsleinstrasse 15, D-97080, Würzburg, Federal Republic of Germany

    G. Münch & Y. Taneli

  2. Cassella AG, CNS-Pharmacology, Frankfurt/Main, Federal Republic of Germany

    E. Schraven & U. Schindler

  3. Theodor-Boveri-Institute, Physiological Chemistry, University of Würzburg, Federal Republic of Germany

    R. Schinzel & D. Palm

Authors
  1. G. Münch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Y. Taneli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. Schraven
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. U. Schindler
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R. Schinzel
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D. Palm
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. P. Riederer
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Münch, G., Taneli, Y., Schraven, E. et al. The cognition-enhancing drug tenilsetam is an inhibitor of protein crosslinking by advanced glycosylation. J Neural Transm Gen Sect 8, 193–208 (1994). https://doi.org/10.1007/BF02260940

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02260940

Keywords

Search

Navigation